SLC5A2 and type 2 diabetes mellitus: Therefore, we hypothesized that the administration of SGLT2 inhibitors could reduce the EFV in patients with type 2 diabetes, and its reduction could be correlated with the changes in insulin sensitivity, body fat, and secretion of adipokines or cytokines, all of which are associated with cardiovascular events.